SunTrust Robinson Remains a Hold on DaVita

By Jason Carr

In a report released today, David S Macdonald from SunTrust Robinson reiterated a Hold rating on DaVita (NYSE: DVA), with a price target of $80. The company’s shares opened today at $72.07.

According to TipRanks.com, Macdonald is a 4-star analyst with an average return of 7.0% and a 65.8% success rate. Macdonald covers the Services sector, focusing on stocks such as American Renal Associates Holdings Inc, Encompass Health Corporation, and Fresenius Medical Care Corp.

Currently, the analyst consensus on DaVita is Moderate Buy and the average price target is $84.60, representing a 17.4% upside.

In a report released yesterday, RBC Capital also reiterated a Hold rating on the stock with a $70 price target.

The company has a one-year high of $80.71 and a one-year low of $52.51. Currently, DaVita has an average volume of 1.78M.

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DaVita, Inc. engages in the provision of medical care services. It operates through the following business segments: Kidney Care and HealthCare Partners. The Kidney Care segment focuses on the delivery of dialysis services to patients with chronic kidney failure and end stage renal disease.